A founding member of the Biosimilars Forum has withdrawn its membership from the organization. Amgen has confirmed to The Center for Biosimilars® that it gave up its membership in the group in September of this year.
A founding member of the Biosimilars Forum has withdrawn its membership from the organization. Amgen has confirmed to The Center for Biosimilars® that it gave up its membership in the group in September of this year.
In a statement provided to The Center for Biosimilars®, Amgen said that it supports the Forum’s mission to advance biosimilars and improve access to biologic therapies, but that the parties disagreed on how best to support the development of a vibrant US market for biosimilars. Amgen emphasized that its priorities include promoting scientifically appropriate development standards for biosimilarity and interchangeability, development of a level playing field to achieve lower costs and long-term stability in the marketplace, enactment of policies that support innovation and acceptance of biosimilars, and the promotion of science-based education for stakeholders.
“As a manufacturer of both originator biologics and biosimilar medicines, Amgen is fully committed to the success of the biosimilars market and to our biosimilars portfolio of 10 biosimilars—2 approved in the United States and 3 approved in the European Union—which target important biological medicines,” said Scott Foraker, vice president and general manager of Amgen’s biosimilars business unit. “To achieve the promised savings in the US healthcare system from biosimilars, we need to advance policies that create a level-playing field, foster biosimilar competition and instill physician and patient confidence.”
While Amgen did not specify where its objectives diverged from those of the Biosimilars Forum, the withdrawal follows the August 2018 filing of a citizen petition by a fellow Forum member, Pfizer, on communications about biosimilars.
In the petition, Pfizer cited multiple communications from reference biologic product sponsors that it characterized as misleading, including an April 13, 2018, tweet from Amgen that suggested that patients could react differently to biosimilars than to reference products. The petition also highlighted an Amgen-sponsored YouTube video that implied that switching to a biosimilar was undesirable for a patient who is well controlled on a reference product.
“Misleading statements like these, and the net impression conveyed by such materials, create undue confusion as to biosimilarity and interchangeability, inflate the risks associated with a physician-directed switch to a biosimilar, and cast doubt on the safety and efficacy of biosimilars generally,” read the petition.
This month, Novartis, parent company of Sandoz, another Forum member, expressed its support for Pfizer’s petition, highlighting the need for additional FDA action and oversight “to help ensure a truthful environment exists within which healthcare providers and patients can make treatment decisions without harmful misinformation about biosimilars.”
The Biosimilars Forum declined to comment on Amgen’s withdrawal.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.